Straits Times Index
3,244.44 +31.80 (+0.99%) Nikkei
27,476.87 +91.62 (+0.33%) Hang Seng
19,715.93 -199.75 (-1.00%) FTSE 100
7,405.45 0.00 (0.00%) Bitcoin USD
27,798.35 +260.40 (+0.95%) CMC Crypto 200
604.38 -14.01 (-2.26%)
UroGen Pharma Ltd. (0XOD.L)
- Business Wire
UroGen Pharma Reports Highest Revenue Quarter and Significant Full Year 2022 Growth and Recent Corporate Developments
PRINCETON, N.J., March 16, 2023--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the fourth quarter and full year ended December 31, 2022, and overview of recent developments.
- Business Wire
UroGen Pharma to Report Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 16, 2023
PRINCETON, N.J., March 09, 2023--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report fourth quarter and full-year 2022 financial results on Thursday, March 16, 2023, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time.
- Business Wire
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J., March 06, 2023--UroGen Pharma Ltd. (Nasdaq: URGN) a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units ("RSUs") to 7 new employees in connection with their entering into employment with UroGen. The grants were made between March 1, 2023 and March 6, 2023. These new team members will support the ongoing commercial launch of Jelmyto® (mitomycin
